Becton, Dickinson and Company (BDX) Stake Boosted by Bradley Foster & Sargent Inc. CT

Bradley Foster & Sargent Inc. CT increased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 6.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,011 shares of the medical instruments supplier’s stock after acquiring an additional 1,299 shares during the period. Bradley Foster & Sargent Inc. CT owned about 10,111.61% of Becton, Dickinson and worth $4,509,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Almanack Investment Partners LLC. bought a new position in Becton, Dickinson and during the first quarter valued at $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in Becton, Dickinson and by 55.8% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after purchasing an additional 240 shares during the period. Parkside Financial Bank & Trust grew its holdings in Becton, Dickinson and by 8.1% during the second quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock valued at $133,000 after purchasing an additional 51 shares during the period. Harfst & Associates Inc. grew its holdings in Becton, Dickinson and by 46.4% during the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 221 shares during the period. Finally, Financial Architects Inc grew its holdings in Becton, Dickinson and by 8.0% during the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after purchasing an additional 54 shares during the period. 86.01% of the stock is owned by institutional investors.

Shares of Becton, Dickinson and Company (BDX) opened at $218.04 on Monday. The company has a debt-to-equity ratio of 1.48, a current ratio of 5.56 and a quick ratio of 5.01. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $225.23. The stock has a market capitalization of $49,889.07, a price-to-earnings ratio of 23.10, a P/E/G ratio of 1.72 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. During the same quarter last year, the business posted $2.12 earnings per share. The firm’s revenue was down 2.0% compared to the same quarter last year. analysts expect that Becton, Dickinson and Company will post 10.63 EPS for the current fiscal year.

BDX has been the subject of several research reports. Piper Jaffray Companies reissued a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Zacks Investment Research lowered Becton, Dickinson and from a “hold” rating to a “sell” rating in a report on Monday, October 9th. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $210.00 price target on shares of Becton, Dickinson and in a report on Wednesday, October 25th. Wells Fargo & Company started coverage on Becton, Dickinson and in a report on Friday, September 22nd. They issued an “outperform” rating and a $225.00 price target for the company. Finally, Bank of America Corporation reaffirmed a “buy” rating and issued a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $213.47.

In related news, insider Stephen Sichak sold 11,787 shares of the stock in a transaction on Friday, September 8th. The stock was sold at an average price of $200.46, for a total value of $2,362,822.02. Following the sale, the insider now owns 14,038 shares in the company, valued at $2,814,057.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Linda M. Tharby sold 4,695 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total value of $941,253.60. Following the sale, the executive vice president now owns 18,670 shares in the company, valued at approximately $3,742,961.60. The disclosure for this sale can be found here. Insiders sold 53,187 shares of company stock worth $10,720,847 in the last quarter. 1.40% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Becton, Dickinson and Company (BDX) Stake Boosted by Bradley Foster & Sargent Inc. CT” was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2017/11/13/becton-dickinson-and-company-bdx-stake-boosted-by-bradley-foster-sargent-inc-ct.html.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply